Herantis Pharma selected for European Innovation Council (EIC) grant of €2.5 million

Herantis Pharma Plc, Company release, insider information, 19 December 2022 at 5:28 p.m. EET


The EIC will, pending final negotiation, grant Herantis with EUR 2.5 million through their prestigious EIC Accelerator, with the option to receive additional funding through an equity investment.


Herantis Pharma Plc ("Herantis") developing disease-modifying therapies for Parkinson’s disease, announced today that it has been invited to negotiate a grant agreement with EIC. This grant will fund the further development of Herantis’ lead product HER-096 for Parkinson’s disease. Herantis’ application successfully passed the EIC Accelerator three-stage evaluation process; in the final stage EIC Jury of independent experts made a recommendation of funding of Herantis’ proposal. Herantis will provide additional information following the conclusion of negotiations with EIC.


About EIC Accelerator:

The EIC Accelerator grants funding and investments through the EIC Fund for individual start-ups and small companies to develop and scale up game-changing innovations. More information about EIC Accelerator: https://eic.ec.europa.eu/eic-funding-opportunities/eic-accelerator-0_en


For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com


Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400


Company website: www.herantis.com


About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.


The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.herantis.com.


Forward-looking statements

This company release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of operations, the Company’s strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “should” or “will” or the negative of such terms or other comparable terminology.


By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company’s actual results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis’ strategy, risks and uncertainties associated with the development and/or approval of Herantis’ drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis’ potential market and industry, Herantis’ freedom to operate  in respect of the products it develops (which freedom may be limited, e.g., by competitors’ patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors.


In addition, even if Herantis’ historical results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.